Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Sells $38,829.00 in Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 12,943 shares of the stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $3.00, for a total transaction of $38,829.00. Following the completion of the sale, the chief financial officer now owns 355,376 shares in the company, valued at $1,066,128. The trade was a 3.51 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Thomas Catinazzo also recently made the following trade(s):

• On Monday, April 28th, Thomas Catinazzo sold 2,690 shares of Relay Therapeutics stock. The shares were sold at an average price of $3.17, for a total transaction of $8,527.30.
• On Thursday, March 27th, Thomas Catinazzo sold 4,864 shares of Relay Therapeutics stock. The shares were sold at an average price of $2.84, for a total value of $13,813.76.
• On Thursday, January 30th, Thomas Catinazzo sold 20,791 shares of Relay Therapeutics stock. The stock was sold at an average price of $4.42, for a total value of $91,896.22.

Relay Therapeutics Trading Down 1.2 %

RLAY stock opened at $3.25 on Friday. Relay Therapeutics, Inc. has a 12-month low of $1.78 and a 12-month high of $10.72. The business’s 50-day moving average is $2.95 and its 200 day moving average is $4.19. The stock has a market cap of $550.95 million, a price-to-earnings ratio of -1.25 and a beta of 1.70.

Relay Therapeutics (NASDAQ:RLAY) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.12. As a group, equities analysts forecast that Relay Therapeutics, Inc. will post -2.55 EPS for the current fiscal year.

Analyst Ratings Changes

RLAY has been the topic of several recent research reports. The Goldman Sachs Group lowered their price objective on Relay Therapeutics from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th. Stifel Nicolaus dropped their price target on shares of Relay Therapeutics from $27.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th. Wells Fargo & Company started coverage on shares of Relay Therapeutics in a research note on Thursday, April 17th. They set an “equal weight” rating and a $4.00 target price on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of Relay Therapeutics in a research note on Friday, March 7th. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Relay Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $18.36.

Institutional Investors Weigh In On Relay Therapeutics

A number of large investors have recently modified their holdings of RLAY. Martingale Asset Management L P grew its stake in Relay Therapeutics by 3.5% during the 4th quarter. Martingale Asset Management L P now owns 80,371 shares of the company’s stock valued at $331,000 after acquiring an additional 2,700 shares in the last quarter. Virtus ETF Advisers LLC grew its position in shares of Relay Therapeutics by 26.2% in the fourth quarter. Virtus ETF Advisers LLC now owns 14,873 shares of the company’s stock valued at $61,000 after purchasing an additional 3,092 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Relay Therapeutics by 1.5% in the fourth quarter. The Manufacturers Life Insurance Company now owns 218,872 shares of the company’s stock valued at $902,000 after purchasing an additional 3,325 shares in the last quarter. Summit Investment Advisors Inc. increased its holdings in shares of Relay Therapeutics by 41.9% in the fourth quarter. Summit Investment Advisors Inc. now owns 12,730 shares of the company’s stock valued at $52,000 after purchasing an additional 3,760 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC lifted its position in Relay Therapeutics by 160.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 6,500 shares of the company’s stock worth $27,000 after buying an additional 4,000 shares in the last quarter. Hedge funds and other institutional investors own 96.98% of the company’s stock.

About Relay Therapeutics

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.